OVERVIEW

The Joint COMydAL, COLYM, MPNCo&D, and 6th Annual Meeting of the International Academy for Clinical Hematology (IACH) is organized by CME Congresses Ltd and will be held from Oct 05 - 07, 2023 at New Cap Event Center, Paris, Ile-de-France, France.

Description:
The field of hematology continues to make significant progress, even in these challenging times. We have seen fascinating developments, especially in the fields of MDS, AML and ALL, Lymphoma, and MPN.

The joint 2023 IACH Meeting will continue to serve as a unique forum where the most compelling and controversial topics facing clinicians are presented. The program will provide a platform to interact and discuss with leading experts many key and developing issues in clinical hematology and within these specialized fields.

COMydAL Program

Friday, October 6, 2023
	Hall A
	MDS-AML-ALL (COMydAL)
09:15-10:45	Session 1: Classification, risk stratification & response assessment updates for MDS
	Moderator: Ana Alfonso Piérola, Spain
09:15-09:30	Prognostication updates: Matteo Della Porta, Italy
09:30-09:45	Classification updates: Leonor Arenillas, Spain
09:45-10:00	Response assessment updates: Amer Zeidan, USA
10:00-10:15	Is MRD assessment ready for use in MDS? Arjan van de Loosdrecht, Netherlands
10:15-10:45	Roundtable discussion: All session faculty
10:45-11:15	Coffee Break
11:15-12:45	Session 2: Management of lower risk MDS
	Moderator: David Valcárcel, Spain
11:15-11:30	ESA/Lenalidomide/IST/chelation: María Díez Campelo, Spain
11:30-11:45	What is the role for chelation in MDS? Eolia Brissot, France
11:45-12:00	Imetelstat/TGF-beta/Roxadustat: Valeria Santini, Italy
12:00-12:15	Early phase agent review: Rami Komrokji, USA
12:15-12:45	Roundtable discussion: All session faculty
12:45-13:15	Lunch Box Pick-up and Break
	COMydAL Program Pause
14:45-16:15	Session 3: Management of higher risk MDS
	Moderator: Marie Sébert, France
14:45-15:00	Injectable and oral HMAs: Pierre Fenaux, France
15:00-15:15	Novel agents in advanced trials (Magro/Sabato): Guillermo Sanz, Spain
15:15-15:30	IDH inhibitors for MDS: Lionel Ades, France
15:30-15:45	Transplant considerations in MDS: Ibrahim Yakoub-Agha, France
15:45:16:15	Roundtable discussion: All session faculty
16:15-16:30	Coffee Break
16:30-18:00	Session 4: Prognosis, MRD and transplantation for AML
	Moderator: Agnieszka Wierzbowska, Poland
16:30-16:45	How do I use molecular data in clinical care of MDS and AML patients: Lisa Pleyer, Austria
16:45-17:00	What is the role of MRD in AML? Michael Heuser, Germany
17:00-17:15	How should we manage patients with MDS/AML? Raphael Itzykson, France
17:15-17:30	Should we use maintenance therapy post-transplant? Lars Bullinger, Germany
17:30-18:00	Roundtable discussion: All session faculty

Saturday, October 7, 2023
	Hall A
	MDS-AML-ALL (COMydAL)
09:00-10:30	Session 5: Updates in AML management in 2023 – Agents in clinic
	Moderator: Jessica Altman, USA
09:00-09:15	What is standard frontline therapy for fit patients in 2023? Jessica Altman, USA
09:15-09:30	What is standard frontline therapy for unfit patients in 2023? Amer Zeidan, USA
09:30-09:45	How do I manage relapsed/refractory AML in 2023? Andrew Wei, Australia
09:45-10:00	Do triplets have a place in current practice of AML? Gail Roboz, USA
10:00-10:30	Roundtable discussion: All session faculty
10:30-11:00	Coffee Break
11:00-12:30	Session 6: Updates in AML management in 2023 – Investigational approaches
	Moderator: Marion Subklewe, Germany
11:00-12:30	Which agents in development have the most promise? Thomas Cluzeau, France
11:15-11:30	Immune investigational approaches (ADCs, Bites, CAR T cells, ICB): Marion Subklewe, Germany
11:30-11:45	Options for patients with TP53 mutant MDS/AML? Naval Daver, USA
11:45-12:00	Updates in mechanisms of resistance in AML and how to overcome them: Klaus Metzeler, Germany
12:00-12:30	Roundtable discussion: All session faculty
12:30-13:00	Lunch Box Pick-up and Break
	COMydAL Program Pause
14:45-16:15	Session 7: How do I manage ALL in 2023?
	Moderator: Elias Jabbour, USA
14:45-15:00	Ph -ve ALL: Robin Foà, Italy
15:00-15:15	Ph +ve ALL: Elias Jabbour, USA
15:15-15:30	T-cell ALL: Nicola Gökbuget, Germany
15:30-15:45	Cellular therapy and transplant considerations for ALL: Sridhar Chaganti, UK
15:45:16:15	Roundtable discussion: All session faculty
16:15-16:30	Coffee Break
16:30-17:00	IACH Closing Plenary Lecture

COLYM Program

Friday, October 6, 2023
	Hall B
	Lymphoma (COLYM)
09:15-10:45	Session 1: What’s new in the field of lymphomas? Keynote lectures
	Moderators: Stefano Luminari, Italy; Anna Sureda, Spain
	Debate: Bringing genomics to the clinic in DLBCL:
09:15-09:35	The pathologist point of view: Miguel Angel Piris, Spain
09:35-09:55	The clinician point of view: Andrew Davies, UK
09:55-10:15	Prognostic factors for cellular therapy strategies: Alberto Mussetti, Spain
10:15-10:45	Roundtable discussion: All session faculty
10:45-11:15	Coffee Break
11:15-12:45	Session 2: CLL and Richter’s syndrome
	Moderators: Mehdi Hamadani, USA; Farrukh Awan, USA
11:15-11:35	Front line therapy in CLL: Time limited vs continuous: Farrukh Awan, USA
11:35-11:55	High risk CLL in the era of BTKi and BCL2 inhibitors: Is allo-HCT still a valid option? Mohamed Kharfan-Dabaja, USA
	Debate: Best therapeutic option of Richter’s syndrome is:
11:55-12:05	Novel agents: Farrukh Awan, USA
12:05-12:15	Allo-HCT: Alex Herrera, USA
12:15-12:25	CAR T cells: Sairah Ahmed, USA
12:25-12:45	Roundtable discussion: All session faculty
12:45-13:15	Lunch Box Pick-up and Break
	COLYM Program Pause
14:45-16:15	Session 3: Follicular lymphoma
	Moderators: Mehdi Hamadani, USA; Mohamed Kharfan-Dabaja, USA
	Debate: Best option for treatment naïve FL patients is:
14:45-15:00	Chemo free strategies: Julio Chavez, USA
15:00-15:15	R-chemo strategies: Pau Abrisqueta, Spain
	Debate: Sequencing treatment in RR FL patients:
15:15-15:30	Bispecific MoAb before CAR T cells are the SOC: Alex Herrera, USA
15:30-15:45	CAR T cells before bispecific MoAb are the SOC: Mazyar Shadman, USA
15:45-16:15	Roundtable discussion: All session faculty
16:15-16:30	Coffee Break
16:30-18:00	Session 4: Diffuse large B cell lymphomas
	Moderators: Anna Sureda, Spain; Alex Herrera, USA
	Debate: Is R-CHOP still the SOC for first-line therapy in DLBCL?
16:30-16:45	Yes: Marek Trn?ný, Czech Republic
16:45-17:00	No: Hervé Tilly, France
	Debate: Most feasible option for 3L therapy in DLBCL patients:
17:00-17:15	CD19 autologous CAR T cells: Anna Sureda, Spain
17:15-17:30	CD20-CD3 bispecific monoclonal antibodies: Elly Lugtenburg, Netherlands
17:30-18:00	Roundtable discussion: All session faculty

Saturday, October 7, 2023
	Hall B
	Lymphoma (COLYM)
09:00-10:30	Session 5: Peripheral T cell lymphomas
	Moderators: Mohamed Kharfan-Dabaja, USA; Julio Chavez, USA
09:00-09:15	Insights in molecular pathology of PTCL: Laurence de Leval, Switzerland
	Debate: PTCL NOS in CR1:
09:15-09:30	SOC is watchful waiting: Eva Domingo-Doménech, Spain
09:30-09:45	SOC is auto-HCT: Graham Collins, UK
	Debate: RR T cell NHL:
09:45-10:00	Novel agents in R/R T cell lymphomas: Christopher Fox, UK
10:00-10:15	Allogeneic transplant in R/R T cell lymphomas: Mehdi Hamadani, USA
10:15-10:30	Roundtable discussion: All session faculty
10:30-11:00	Coffee Break
11:00-12:30	Session 6: Hodgkin’s lymhoma
	Moderators: Stefano Luminari, Italy; Anna Sureda, Spain
11:00-11:20	The role of radiotherapy in 2023: Lena Specht, Denmark
11:20-11:40	What is the role for response-adapted first-line treatment strategies? Andrea Gallamini, France
11:40-12:00	Is HDT and autoHCT still SOC in the era of novel therapies? Ali Bazarbachi, Lebanon
12:00-12:20	When do I consider allogeneic HCT in cHL previously treated with BV and CKI? Miguel Perales, USA
12:20-12:30	Roundtable discussion: All session faculty
12:30-13:00	Lunch Box Pick-up and Break
	COLYM Program Pause
14:45-15:15	COLYM Plenary Lecture
14:45-15:05	The latest in allogeneic CAR T: Miguel Perales, USA
15:05-15:15	Q&A
15:15-16:15	Session 7: Mantle cell lymphoma
	Moderators: Christopher Fox, UK; Eva Domingo-Doménech, Spain
15:15-15:30	Front line consolidation with high-dose therapy and auto-HCT and post-transplant R maintenance: Should this approach be adandoned? Marek Trn?ný, Czech Republic
	Debate: Best therapy for RR MCL is:
15:30-15:45	Cellular therapy: Alejandro Martín García-Sancho, Spain
15:45-16:00	BTKs: Wojciech Jurczak, Poland
16:00-16:15	Roundtable discussion: All session faculty
16:15-16:30	Coffee Break
16:30-17:00	IACH Closing Plenary Lecture in Hall A

MPNCo&D Program

Friday, October 6, 2023
	Hall C
	Myeloproliferative Neoplasms (MPNCo&D)
09:15-10:45	Session 1: Polycythemia Vera in 2023 and beyond
	Moderators: Naveen Pemmaraju, USA; Claire Harrison, UK & Ruben Mesa, USA
	Debate: Standard of care in PV
09:15-09:25	Thrombosis/risk stratification in PV – aiming for a normal PBC: Mary Frances McMullin, UK
09:25-09:35	IFN in PV – with molecular monitoring: Jean-Jacques Kiladjian, France
09:35-09:50	PTG-300/Rusfertide: from bench to bedside – Hepcidin Mimetics in PV: Ronald Hoffman, USA
	Debate: All PV patients should be treated
09:50-10:00	Yes, including lower-risk: Tiziano Barbui, Italy
10:00-10:10	No, only higher risk: Ruben Mesa, USA
10:10-10:25	Should we still use HU for PV – can RUX go to the front line? Claire Harrison, UK
10:25-10:45	Roundtable discussion: All session faculty
10:45-11:15	Coffee Break
11:15-12:45	Session 2: Essential thrombocytosis – Can we do better?
	Moderators: Claire Harrison, UK; Anna Godfrey, UK
11:15-11:35	Higher risk ET: state-of-the-art management in 2023: Claire Harrison, UK
11:35-11:50	What is my approach to triple negative thrombocytosis? Anna Godfrey, UK
11:50-12:10	Should all patients with ET have aspirin? Tiziano Barbui, Italy
12:00-12:30	CALR: role of immunotherapy as future directions/novel approaches: Bethan Psaila, UK
12:30-12:45	Roundtable discussion: All session faculty
12:45-13:00	Lunch Box Pick-up and Break
	MPNCo&D Program Pause
14:45-16:15	Session 3: Myelofibrosis: current and novel approaches in a rapidly developing field
	Moderators: Naveen Pemmaraju, USA; John Mascarenhas, USA
14:45-15:00	Pre-fibrotic MF: a new entity with special considerations: Paola Guglielmelli, Italy
15:00-15:15	Early/lower risk MF: treatment options and approach: Ruben Mesa, USA
15:15-15:30	Int/higher risk MF: current treatment options in 2023: John Mascarenhas, USA
15:30-15:45	Current data for combinations for JAKi naïve patients: Naveen Pemmaraju, USA
15:45-16:00	Clinical and molecular factors, biomarkers of MPN progression: current and future: Adam Mead, UK
16:00-16:15	Anemia in MF: an emerging area for novel approaches: Naveen Pemmaraju, USA
16:15-16:30	Coffee Break
16:30-18:00	Session 4: Treatment of high-risk MF
	Moderators: Florian Heidel, Germany; John Mascarenhas, USA
16:30-16:45	How to define failure of JAKi: Florian Heidel, Germany
16:45-17:00	Current outcomes for transplantation in MF: Maria Robin, France
	Debate: Future directions: Transplantation in MPN
17:00-17:10	Transplant early before patients fail a JAKi: Donal McLornan, UK
17:10-17:20	Patients failing a JAKi can be salvaged without BMT: John Mascarenhas, USA
17:20-17:35	Novel agents in the clinic beyond JAKi: Raajit Rampal, USA
17:35-18:00	Roundtable discussion: All session faculty

Saturday, October 7, 2023
	Hall C
	Myeloproliferative Neoplasms (MPNCo&D)
09:00-10:45	Session 5: AYA MPNs: pregnancy, thromboses and special considerations (ending at 10:45)
	Moderators: Isabelle Plo, France; Ruben Mesa, USA
09:00-09:15	New data for thrombosis in MPN: Anna Falanga, Italy
09:15-09:30	Gastro-oncology: splanchnic vein thrombosis a primer for haematologists: David Patch, UK
09:30-09:45	Cardio-oncology: primer on intersection of cardio-oncology and MPNs: arrythmias, clots, anticoagulation and cardiac considerations: Michael Fradley, USA
09:45-10:00	Pregnancy, fertility and hormone therapy: state-of-the-art considerations: Susan Robinson, UK
10:00-10:15	Young patients with MPNs: unique considerations in thromboses: Jean-Christophe Ianotto, France
10:15-10:30	Latest update on inheritability and MPN: Isabelle Plo, France
10:30-10:45	Roundtable discussion: All session faculty
10:30-11:00	Coffee Break
11:00-12:30	Session 6: Rare MPNs – Focus on emerging subtypes
	Moderators: Deepti Radia, UK; Andreas Reiter, Germany
11:00-11:15	Investigation and management of eosinophilia: Andreas Reiter, Germany
11:15-11:30	Aggressive SM: emerging therapy options: Deepti Radia, UK
11:30-11:45	Current management of CMML: Eric Solary, France
11:45-12:00	Investigation and management of congenital erythrocytosis: Mary Frances McMullin, UK
12:00-12:30	Roundtable discussion: All session faculty
12:30-13:00	Lunch Box Pick-up and Break
	MPNCo&D Program Pause
14:45-16:15	Session 7: Current and future considerations in MPNs and rare hematologic malignancies: building innovative, sustainable programs across the world
	Moderators: Naveen Pemmaraju, USA; Ruben Mesa, USA
14:45-15:00	What is patient advocacy? Jonathan Mathias, UK
15:00-15:15	Building MPN communities and the role of MPN advocates network: Werner Zinkand, Germany
15:15-15:35	Future directions in MPN: AI and MPN: Daniel Royston, UK
15:35-15:55	CHIP and MPNs: what have we learned from population studies in Denmark? Hans Hasselbalch, Denmark
15:55-16:15	Plenary lecture: MPNs and Targeting stem cells in MF: Past, Present and Future: Ronald Hoffman, USA
16:15-16:30	Coffee Break
16:30-17:00	IACH Closing Plenary Lecture in Hall A